Similar articles for PMID: 25009822

Year	Number of Results
1984	1
1992	1
1995	1
1996	1
1997	3
1998	1
1999	1
2000	4
2001	2
2002	1
2003	6
2004	7
2005	1
2006	2
2007	1
2008	2
2009	1
2010	3
2011	1
2012	3
2013	4
2014	12
2015	7
2016	9
2017	11
2018	9
2019	5
2020	5
2021	5
2022	11
2023	2
2024	0

1

A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy.

Chung DS, Shin HJ, Hong YK. Chung DS, et al. J Immunol Res. 2014;2014:326545. doi: 10.1155/2014/326545. Epub 2014 Jun 9. J Immunol Res. 2014. PMID: 25009822 Free PMC article. Review.

2

Cellular immunotherapy for malignant gliomas.

Lin Y, Okada H. Lin Y, et al. Expert Opin Biol Ther. 2016 Oct;16(10):1265-75. doi: 10.1080/14712598.2016.1214266. Epub 2016 Jul 29. Expert Opin Biol Ther. 2016. PMID: 27434205 Free PMC article. Review.

3

Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma.

Wildes TJ, Grippin A, Dyson KA, Wummer BM, Damiani DJ, Abraham RS, Flores CT, Mitchell DA. Wildes TJ, et al. Clin Cancer Res. 2018 Aug 15;24(16):3955-3966. doi: 10.1158/1078-0432.CCR-17-3061. Epub 2018 Apr 30. Clin Cancer Res. 2018. PMID: 29712687 Free PMC article.

4

Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy.

Chuntova P, Downey KM, Hegde B, Almeida ND, Okada H. Chuntova P, et al. Front Immunol. 2019 Jan 22;9:3062. doi: 10.3389/fimmu.2018.03062. eCollection 2018. Front Immunol. 2019. PMID: 30740109 Free PMC article. Review.

5

T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment.

Kwok D, Okada H. Kwok D, et al. J Neurooncol. 2020 Apr;147(2):281-295. doi: 10.1007/s11060-020-03450-7. Epub 2020 Mar 17. J Neurooncol. 2020. PMID: 32185647 Free PMC article. Review.

6

Adoptive cell transfer therapy for malignant gliomas.

Ishikawa E, Takano S, Ohno T, Tsuboi K. Ishikawa E, et al. Adv Exp Med Biol. 2012;746:109-20. doi: 10.1007/978-1-4614-3146-6_9. Adv Exp Med Biol. 2012. PMID: 22639163 Review.

7

[Immunotherapy in brain tumors].

De Carli E, Delion M, Rousseau A. De Carli E, et al. Ann Pathol. 2017 Feb;37(1):117-126. doi: 10.1016/j.annpat.2016.12.001. Epub 2017 Jan 19. Ann Pathol. 2017. PMID: 28111040 Review. French.

8

The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain.

Weller M, Fontana A. Weller M, et al. Brain Res Brain Res Rev. 1995 Sep;21(2):128-51. doi: 10.1016/0165-0173(95)00010-0. Brain Res Brain Res Rev. 1995. PMID: 8866671 Review.

9

Immunotherapy in gliomas: limitations and potential of natural killer (NK) cell therapy.

Ogbomo H, Cinatl J Jr, Mody CH, Forsyth PA. Ogbomo H, et al. Trends Mol Med. 2011 Aug;17(8):433-41. doi: 10.1016/j.molmed.2011.03.004. Epub 2011 Apr 19. Trends Mol Med. 2011. PMID: 21507717 Review.

10

Current update of adoptive immunotherapy using cytokine-induced killer cells to eliminate malignant gliomas.

Ryu JI, Han MH, Cheong JH, Kim JM, Kim CH. Ryu JI, et al. Immunotherapy. 2017 Mar;9(5):411-421. doi: 10.2217/imt-2017-0003. Immunotherapy. 2017. PMID: 28357913 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

114 results

Results by year